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Worsening calcification 
propensity precedes all-cause 
and cardiovascular mortality in 
haemodialyzed patients
Georg Lorenz1, Dominik Steubl1, Stephan Kemmner1, Andreas Pasch2, Wilhelm Koch-
Sembdner1, Dang Pham1, Bernhard Haller3, Quirin Bachmann1, Christopher C. Mayer  4, 
Siegfried Wassertheurer4, Susanne Angermann1, Maciej Lech1, Philipp Moog1, Axel Bauer5, 
Uwe Heemann1 & Christoph Schmaderer1
A novel in-vitro test (T50-test) assesses ex-vivo serum calcification propensity which predicts mortality in 
HD patients. The association of longitudinal changes of T50 with all-cause and cardiovascular mortality 
has not been investigated. We assessed T50 in paired sera collected at baseline and at 24 months in 188 
prevalent European HD patients from the ISAR cohort, most of whom were Caucasians. Patients were 
followed for another 19 [interquartile range: 11–37] months. Serum T50 exhibited a significant decline 
between baseline and 24 months (246 ± 64 to 190 ± 68 minutes; p < 0.001). With serum Δ-phosphate 
showing the strongest independent association with declining T50 (r = −0.39; p < 0.001) in multivariable 
linear regression. The rate of decline of T50 over 24 months was a significant predictor of all-cause 
(HR = 1.51 per 1SD decline, 95% CI: 1.04 to 2.2; p = 0.03) and cardiovascular mortality (HR = 2.15; 
95% CI: 1.15 to 3.97; p = 0.02) in Kaplan Meier and multivariable Cox-regression analysis, while cross-
sectional T50 at inclusion and 24 months were not. Worsening serum calcification propensity was an 
independent predictor of mortality in this small cohort of prevalent HD patients. Prospective larger 
scaled studies are needed to assess the value of calcification propensity as a longitudinal parameter for 
risk stratification and monitoring of therapeutic interventions.
Disturbed calcium and phosphate homeostasis, vascular disease progression and excess mortality, largely attribut-
able to cardiovascular (CV) causes, remain unresolved issues in haemodialysis (HD) patients1–3. Non-traditional 
risk factors, e.g. chronic inflammation, malnutrition and aberrant bone turn over gain increasing importance 
along with declining renal function4. Besides monitoring and targeting calcium and phosphate, the physiological 
humoral system, which resists the formation of calcium-phosphate-nanocrystal-formation in biological fluids, 
has largely been neglected.
Recently, Pasch et al. developed an in-vitro test (T50-test), that time-dependently assesses the calcification 
propensity of human serum in the presence of supersaturating doses of calcium and phosphate5,6. In this pro-
cess, amorphous primary calciprotein particles (CPP) spontaneously grow into crystallized secondary CPP5. The 
transformation time T50 is thought to reflect the complex interplay of anti- and pro-calcifying serum components, 
such as calcium and phosphate on the one and such as magnesium, fetuin-A and albumin on the other hand5–7. 
A shorter T50 time was associated with accelerated vascular stiffness progression and overall mortality in chronic 
kidney disease stage III-IV7. Lower T50 values were also shown to predict graft failure, CV and all-cause mortality 
in renal transplant recipients8,9.
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A recently published study revealed a moderate, yet independent association of decreased serum T50 
with mortality and CV endpoints in patients of the original “Evaluation of Cinacalcet Therapy to Lower 
Cardiovascular Events” (EVOLVE) trial10,11. These data originate from 2785 HD patients with secondary hyper-
parathyroidism10,11. The moderate predictive capacity of T50 for all-cause mortality (HR = 1.1 per 1 SD lower T50) 
in the EVOLVE cohort was somewhat surprising considering that “pro-calcific pressure” should be particularly 
high in HD patients10,12. Interestingly, individual serum calcification propensity (T50-value) is to a large extent 
genetically determined13. This finding led us to hypothesize that it might not only be the absolute T50-value at a 
given time point, which mediated the risk of dialysis patients. Alternatively, changes to the individual’s resilience 
against CPP formation – a decline in T50 – throughout dialysis dependency might mirror risk more accurately. We 
therefore assessed T50 from serum samples collected at baseline and after 24 months in 188 HD patients to test if 
intra-individual changes in T50 precede mortality.
Results
This study was performed in a subgroup of 188 European haemodialysis patients of the ISAR cohort who were 
still alive and active in the study after the first follow up (FU) period of 24 months with a maximum spread 
of ± 3.2 months and for whom sera were available at both baseline and FU. Patients for whom timely 24 [23–25] 
months FU had been missed were excluded a priori (Fig. 1). Most patients were of Caucasian ethnicity with only 
four black (2%) and two Chinese (1%) participants.
In comparison with the total cohort, the study population did not significantly differ with regard to demo-
graphic parameters, body mass index (BMI) and dialysis modality. Included patients were, by nature of the 
study design, enriched for survivors (22.9% versus 35.8% all-cause mortality in the total cohort; p < 0.001). 
Additionally, history of myocardial infarction (14.4% versus 19.8%; p = 0.02) and use of central venous catheters 
(2.7% versus 7.3%; p = 0.001) at baseline were less frequent among included patients. Median albumin levels 
were slightly higher in the study population (41 g/l versus 40 g/l, p = 0.04). For details please see supplementary 
Table 1.
Serum calcification propensity declines in stable haemodialysis patients. Both T50Baseline and 
T50Follow up values were nearly normally distributed in this cohort (Supplementary Figure 1). Mean T50 values were 
246 ± 64 minutes at baseline and 190 ± 68 minutes at time of 24 months FU indicating a significantly declining 
T50 over time (p < 0.001; Fig. 2A). In accordance, the histogram of T50Change was skewed towards negative values 
(Fig. 2B). Of 188 patients included 31 (16%) presented with increasing T50 values. 18 (10%) patients showed 
stable values as defined by T50Change = 0 ± 5,1% (5,1% was the inter-assay coefficient for T50 standards at 260 min 
in the EVOLVE cohort)10. Remarkably, a total of 106 (77%) patients presented declining T50 values (T50Change < 
−5,1%) during 24 months of FU (Fig. 2B).
Description of the study cohort and factors associated with declining T50 (low T50Change). Table 1 
displays the characteristics of the study population stratified by median T50Change (above or below −22.7%) or 
by median absolute T50Follow up (above or below 192.5 min) at time of 24 months FU. Median age of the entire 
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death before first follow up: n = 101
renal transplantaon 
            before first follow up: n = 24
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all-cause mortality n = 43
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            before first follow up: n = 9
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Figure 1. Observation schedule, endpoints and selection of the study population; Patients were selected per 
predefined criteria stated in “methods”. Dotted arrows indicate patients not selected or leaving the study. Sera 
were collected at inclusion and after 24 [23–25] months of observation. Patients were then followed up for 
mortality for an average of 19 [11; 37] months.
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cohort was 71 [57–78] years. Comparing the subgroups generated by medians, no significant associations were 
detectable for T50Change with age, pre-existing comorbidities (including the adapted CCI) and intake of phosphate 
lowering drugs. However, in univariate analysis, increased serum phosphate was higher in those with T50Change 
below the median (1.7± 0.5 versus 1.5 ± 0.4 mmol/l, p < 0.001). Interestingly, Δ phosphate (=phosphateFollow up 
– phosphateBaseline) was also distributed differently among individuals above and below the median of T50Change 
(Table 1). Whereas in the total study population absolute phosphate levels tended to decline between baseline 
(1.7 ± 0.5 mmol/l) and FU (1.6 ± 0.5 mmol/l; p = 0.003), patients with declining T50 values (T50Change < −5.1%) 
presented with stable high phosphate levels (1.7 ± 0.5 mmol/l; ppaired t-test = 0.31). Subjects presenting with stable or 
increasing T50 at baseline and 24 months FU showed declining phosphate levels between baseline and 24 months 
FU (1.8 versus 1.5 ± 0.4 mmol/l, respectively; p < 0.001). Both groups did not significantly differ in phosphate 
levels measured at baseline (p = 0.43) but exhibited significantly different phosphate at 24 months FU (Fig. 3A). 
Δ phosphate was significantly correlated with T50Change (r = −0.39; p < 0.001; Fig. 3B), suggesting a permanently 
elevated or increasing phosphate associates with declining T50. Δ phosphate remained the strongest regressor of 
T50Change in multivariable linear regression (β = −8.4; 95%CI: −13.1 to−3.6; p = 0.001). R² of the model created 
was 0.24 - “(enter method)”. Additionally, Kt/V was a significant regressor of T50Change (β = 5.4; 95% CI: 0.8 to 9.9; 
p = 0.001; Table 2). Of note, lower absolute T50 at FU was associated with higher parathyroid hormone and IL-6 
levels (p = 0.01 and 0.03 respectively, Table 1).
Declining T50 predicts all-cause and cardiovascular mortality in haemodialysis patients. After 
24 months of observation, patients were followed up for all-cause (n = 43) and CV mortality (n = 17) for a median 
of 19 [11–35] months. Three patients underwent renal transplantation and 12 were lost to FU (Fig. 1). In Kaplan 
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Figure 2. Absolute T50 at baseline and FU and percentage decline of T50; (A) Absolute T50 values at baseline 
(white boxplot) and at 24 months FU (grey boxplot). (B) Histogram stating the frequencies of T50Change 
((=T50Follow up − T50Baseline)/(T50Baseline)) of n = 188 Patients. (C) Individual patients were sorted in descending 
order per their T50Change values. Patients displaying a decline in T50 (defined by T50Change < −5.1%; 5,1% was the 
inter-assay coefficient for T50 standards at 260 min in the EVOLVE cohort) were stained red. Absolute number 
of patients and (percent of total) are reported with dashed rectangles. The same colour code was used to stain 
the histogram in B.
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Parameter
Study 
cohort(a) 
(n = 188)
Change of T50 [%]
Sign.
Absolute T50
Sign.
LOW (n = 94) 
< −22.7 %
HIGH (n = 94) 
> −22.7 %
LOW (n = 94) 
< 192.5 min
HIGH (n = 94) 
> 192.5 min
Age [y] 71 [57–78] 73 [59–78] 67 [56–77] 0.20 72 [58–78] 69 [56–79] 0.65
Gender [males] 121 (64.4%) 57 (61%) 64 (68.1%) 0.36 59 (63%) 62 (66%) 0.76
BMI [kg/m²] 25.5 ± 5.7 26 ± 6.2 25 ± 5.1 0.04 26.1 ± 6.1 24.9 ± 5.3 0.09
Adapted CCI [0–21] 4 [2–7] 4 [2–6] 4 [1–7.3] 0.69 4 [2–6] 4 [1–7] 0.98
History of MI 21 (11.2%) 10 (11%) 11 (11.7%) 1 7 (7%) 14 (14.9%) 0.16
Hypertension 171 (91%) 87 (93%) 84 (89.4%) 0.61 84 (89%) 87 (92.6%) 0.61
Diabetes 75 (39.9%) 40 (43%) 35 (37.2%) 0.55 37 (39%) 38 (40.4%) 1
Smoking [ever] 83 (44.1%) 43 (46%) 40 (42.6%) 0.78 47 (50%) 36 (38.3%) 0.14
Dyslipidaemia* 91 (48.4%) 45 (48%) 46 (48.9%) 1 45 (48%) 46 (48.9%) 1
COPD 21 (11.2%) 12 (13%) 9 (9.6%) 0.64 15 (16%) 6 (6.4%) 0.06
Cancer 45 (23.9%) 24 (26%) 21 (22.3%) 0.73 26 (28%) 19 (20.2%) 0.31
CHD 69 (36.7%) 34 (36%) 35 (37.2%) 1 33 (35%) 36 (38.3%) 0.76
PAOD 51 (27.1%) 30 (32%) 21 (22.3%) 0.19 24 (26%) 27 (28.7%) 0.74
CerVD 36 (19.1%) 21 (22%) 15 (16%) 0.35 20 (21%) 16 (17%) 0.60
CHF 35 (18.6%) 13 (14%) 22 (23.4%) 0.13 14 (15%) 21 (22.3%) 0.26
Liver fibrosis 12 (6.4%) 4 (4%) 8 (8.5%) 0.37 4 (4%) 8 (8.5%) 0.37
GIT disease 71 (37.8%) 38 (40%) 33 (35.1%) 0.55 43 (46%) 28 (29.8%) 0.04
GIT bleeding 28 (14.9%) 10 (11%) 18 (19.1%) 0.15 9 (10%) 19 (20.2%) 0.06
Rheumatic dis. 4 (2.1%) 3 (1.6%) 1 (0.5%) 0.62 4 (4%) 0 (0%) 0.12
Dementia 2 (1.1%) 1 (0.5%) 1 (0.5%) 1 2 (2%) 0 (0%) 0.50
HD not HDF 109 (87.2%) 52 (90%) 57 (85.1%) 0.59 63 (93%) 46 (80.7%) 0.06
HD-vintage [mos.] 62 [43–98] 62 [45–99] 60 [40–89] 0.26 58 [44–91] 63 [41–99] 0.85
Kt/V 1.5 ± 0.4 1.4 ± 0.4 1.5 ± 0.3 0.09 (a) 1.4 ± 0.4 1.5 ± 0.3 0.03
Catheter present 10 (5.3%) 6 (6%) 4 (4.3%) 0.49 5 (5%) 5 (5.3%) 1
Hgb [g/dl] 11.5 ± 4.7 11.7 ± 6.5 11.3 ± 1.1 0.54 11.8 ± 6.5 11.2 ± 1.2 0.39
Calcium [mmol]† 2.2 ± 0.2 2.2 ± 0.2 2.2 ± 0.2 0.82 2.2 ± 0.2 2.2 ± 0.2 0.79
Δ calcium −0.1 ± 0.2 −0.1 ± 0.2 0 ± 0.2 0.21 −0.1 ± 0.2 −0.1 ± 0.2 0.95
Magnesium [mmol] 0.62 ± 0.11 0.62 ± 0.10 0.63 ± 0.12 0.49 0.61 ± 0.11 0.64 ± 0.12 0.15
Phosphate [mmol] 1.6 ± 0.5 1.7 ± 0.5 1.5 ± 0.4 <0.001 1.8 ± 0.5 1.4 ± 0.3 <0.001
Δ phosphate −0.1 ± 0.5 0 ± 0.5 −0.2 ± 0.5 0.001 0 ± 0.5 −0.2 ± 0.4 0.07
Albumin [g/l] 38.9 ± 3.8 38.5 ± 4.1 39.4 ± 3.3 0.08 38.1 ± 3.9 39.8 ± 3.5 0.002
Δ albumin [g/l] −1.4 ± 4.0 −1.8 ± 4.1 −1.3 ± 0.32 0.11 −1.5 ± 4.1 −1.3 ± 3.2 0.71
Creatinine [mg/dl] 8.6 ± 2.4 8.4 ± 2.1 8.7 ± 2.6 0.38 8.6 ± 2.3 8.5 ± 2.5 0.73
BUN 126.2 ± 33.7 125.3 ± 31.8 127.1 ± 35.5 0.72 127.4 ± 31.9 125 ± 35.4 0.62
iPTH [pg/ml]‡ 216 [106–402] 258 [124–450] 196 [86–360] 0.14 269 [141–424] 188 [77–319] 0.013
IL6 [pg/ml] 5.7 [0–12.8] 6.4 [0.8–12.2] 4.8 [0–13.1] 0.33 7.1 [0.8–13.5] 3.7 [0–10.5] 0.03
Antihypertensives 159 (84.6%) 83 (88%) 76 (80.9%) 0.23 82 (87%) 77 (81.9%) 0.42
VDRA 118 (62.8%) 62 (66%) 56 (59.6%) 0.45 60 (64%) 58 (61.7%) 0.88
Phosphate binders 147 (78.2%) 71 (37.8%) 76 (40.4%) 0.48 75 (80%) 72 (76.6%) 0.72
- calcium cont. 102 (54.3%) 48 (51%) 54 (57.4%) 0.24 41 (44%) 34 (36.2%) 0.46
- others 75 (39.9%) 36 (38%) 39 (41.5%) 0.76 41 (44%) 34 (36.2%) 0.37
Cinacalcet 52 (27,7%) 29 (30.9%) 23 (24.5) 0.42 29 (30.9) 23 (24.5%) 0.42
Statins 79 (42%) 42 (22.3%) 37 (19.7%) 0.56 38 (40%) 41 (43.6%) 0.78
Marcumar 29 (15.4%) 11 (5.9%) 18 (9.6%) 0.23 14 (15%) 15 (16%) 1
Table 1. Characteristics of the study population stratified by median change of T50 and median absolute T50 at 
time of follow up. Age, comorbidities and basic laboratory values at time of 24 months FU; data is expressed as 
mean ± standard deviation (SD), median and [interquartile-range] or counts and (% of superset) for normally 
distributed data unpaired t-test, Mann-Whitney-U- and χ²-test were used for comparison; *Dyslipidaemia: 
diagnosed (medical report) or intake of statins; †two total calcium values were imputed as centres specific mean 
values. ‡12 missing values for intact parathyroid hormone (iPTH); Δ phosphate/Δ calcium/Δ albumin values 
were calculated as valueFollow up−valueBaseline. Abbreviations: Body mass index (BMI); Charlson Comorbidity 
Index (CCI); myocardial infarction (MI); chronic obstructive pulmonary disease (COPD); coronary heart 
disease (CHD); peripheral arterial occlusive disease (PAOD); cerebral vascular disease (CerVD); congestive 
heart failure (CHF); gastrointestinal (GIT); haemodialysis not haemodiafiltration (HD(F)); Interleukin-6 (IL-6); 
Vitamin D receptor activators (VDRA).
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Figure 3. Relation of serum phosphate and T50Change; (A) Left: Absolute phosphate levels at baseline (broadest 
white boxplot) and FU (broadest grey box plot) in the total cohort (n = 188). This cohort was split per T50 
decliners versus T50 non-decliners Middle: Absolute phosphate levels at baseline (white boxplot) and FU (grey 
boxplot) in those that declined in T50 between baseline and FU (T50Change  <  −5.1%); n = 139. Right: Absolute 
phosphate levels at baseline (small white boxplot) and FU (small grey boxplot) in those that had stable or 
increasing T50 (T50Change ≥ −5.1%); n = 49. Differences among groups regarding absolute phosphate levels were 
tested using paired and unpaired t-test as appropriate. (B) Dot plot depicting the correlation of T50Change with ∆ 
phosphate (=phosphate Follow up−phosphate Baseline). T50 decliners and non-decliners were coloured red and blue, 
respectively. Pearson correlation was used to quantify the relation.
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Meier analysis, cumulative incidence of all-cause mortality was significantly higher in patients below the median 
of T50Change (p = 0.02; Fig. 4A). Regarding CV-mortality a similar trend was visible although median T50Change did 
not reach statistical significance (p = 0.05, Fig. 4C and D).
In contrast, stratification of patients by median of T50Follow up didn’t significantly predict all-cause mortality in 
our cohort (Fig. 4B). Likewise, stratification of the study population by T50Baseline was not significantly associated 
with all-cause mortality (Supplementary Figure 2), likely due to the preselection described above.
Considering T50Change on a continuous scale, declining T50 was significantly associated with all-cause mor-
tality in Cox-regression (HR = 1.74 per SD decline; 95%CI: 1,2 to 2,51; p = 0.003). After block-wise adjust-
ment for demographics (age, sex, BMI), comorbidities and basic laboratory parameters, 1SD = 30.5% decline 
in T50 remained associated with a 51% (95%CI: 4–120%; p = 0.03) increased risk for all-cause mortality. 
Likewise, declining T50 was associated with CV mortality (HR = 2.14; 95%CI:1.15 to 3.97; Table 3). Exclusion 
of non-Caucasian study participants (n = 6) did not materially affect the latter results (supplementary Table 4).
By contrast, neither absolute T50Follow up nor T50Baseline remained significant predictors of all-cause mortality in 
the final adjusted model (supplementary Table 2 and supplementary Table 3, respectively) and were relevantly 
associated with CV mortality in our study (not shown).
Discussion
The main findings of this subgroup analysis in chronic haemodialysis patients, were, firstly, that serum calci-
fication propensity T50 declined between baseline and FU. Secondly, that a decline in T50 was accompanied by 
increasing phosphate levels at baseline and 24 months FU. Thirdly, that the intra-individual decline of calcifica-
tion resistance predicts all-cause and cardiovascular mortality in HD patients. These findings suggest that observ-
ing change of T50 might add prognostic value to absolute T50 values in HD patients.
The development of the T50-test was an important step ahead for a more comprehensive assessment of col-
loidal chemical interactions within the complex field of “calcification and calcium x phosphate nanocrystal for-
mation”5,10. Elevated serum phosphate, calcium, low magnesium and fetuin-A levels have long been linked to 
vascular calcification and mortality in ESRD and HD patients14–25. The colloidal chemical nature of the crystal-
lization process per se suggests strong interaction effects amongst these players, which is in line with findings 
from cohort studies16,26–28. In fact, mortality is especially high for patients with both excessively high phosphate 
and calcium serum levels21,28. On the contrary, magnesium appears to dampen the detrimental effects of elevated 
phosphate levels in HD patients16. The strength of the T50-test is that it takes these interactions into account by 
assessing the distal tract of the calcification cascade, i.e. the interaction between calcium and phosphate, which 
takes place in the CPP-forming biological matrix of human serum6. Elevated serum phosphate, calcium and 
lower serum albumin have already been associated with lower absolute T50 at a single time point in CKD and 
HD patients7,10. Our data add further plausibility to this concept by indicating, that high or increasing phos-
phate, parallels declining T50. We did not, however, observe a similar relation for Δ albumin and Δ calcium, 
Parameter 1 SD β - values
95 % confidence 
intervals of β
Standardized β - 
values p - value
Intercept — −20.2 −29.6 to −10.9 — 0.001
Age [years] 14.4 −2.2 −6.5 to 2.2 −0.07 0.33
Sex [male = 1] 5.2 −3.6 to 13.9 0.08 0.24
BMI [kg/m²] 5.7 0.3 −4.1 to 4.7 0.01 0.88
Calcium-containing 
phosphate binders =1 — 7.0 −1.1 to 15.2 0.12 0.09
VDRA intake =1 — −6.9 −15.4 to 1.7 −0.11 0.11
CHD =1 — 7.6 −2 to 17.2 0.12 0.12
PAOD =1 — −7.0 −17.5 to 3.5 −0.1 0.19
Diabetes =1 — −5.5 −14.3 to 3.4 −0.09 0.23
Kt/V 0.4 5.4 0.8 to 9.9 0.17 0.02
Albumin [g/l] 3.8 3.7 −1.3 to 8.7 0.12 0.15
Δ albumin [g/l] 4.0 2.1 −2.4 to 6.6 0.07 0.37
Magnesium [mmol] 0.1 4.0 −0.5 to 8.5 0.12 0.08
calcium [mmol] 0.2 1.7 −3.7 to 7.1 0.06 0.54
Δ calcium [mmol] 0.2 0.4 −4.7 to 5.5 0.01 0.88
Phosphate [mmol] 0.5 −6.9 −11.8 to −2.1 −0.23 0.006
Δ phosphate [mmol] 0.5 −8.4 −13.1 to −3.6 −0.27 0.001
IL-6 [pg/ml] 9.9 0.8 −3.5 to 5.1 0.03 0.727
Table 2. Multivariable linear regression: dependent variable T50Change. Multivariable linear regression with 
T50Change [%] as dependent variable. Corrected R2 of the model was 0.24. Variance of inflation factors were <2 
for all variables. Metric variables were centred on their mean before entering the model. All variables were 
included at once. Patients characteristics at 24 months FU were used for modelling. Δ phosphate, Δ calcium 
and Δ albumin were calculated as valueFollow up−valueBaseline Abbreviations: Body mass index (BMI); Vitamin 
D receptor activators (VDRA); coronary heart disease (CHD); peripheral arterial occlusive disease (PAOD); 
Interleukin-6 (IL-6).
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which might in part be due to a lower variance of these parameters between baseline and 24 months FU in our 
cohort. Nevertheless, our data underscore the importance of controlling serum phosphate levels in HD patients, 
as high or rising phosphate levels may well weaken the natural resistance against the formation of secondary CPP. 
However, given the moderate fit of our linear regression model, besides Δ phosphate or Kt/V other factors will 
also relate to declining T50. Magnesium is such a candidate indicated by our data. Unfortunately, we were unable 
to investigate Δ ionized magnesium levels over time, due to an incomplete magnesium-dataset at baseline.
Given that a short T50 time represents lower resistance to secondary CPP formation5,6, a decline of T50, as 
observed in our study, implies the loss of anti-calcific capacities of biologic fluids. In our cohort, a decline of T50 
occurred over the course of dialysis dependency and was independently associated with all-cause mortality and 
remained associated with cardiovascular mortality after adjustment for potential confounders. As such, the per 
cent decline of T50 between baseline and 24-months reassessment showed a considerably stronger association 
with mortality than absolute T50Follow up. Since absolute T50 values are to a large extent genetically determined in 
the general population13, it appears plausible that the dynamics of T50 predict future risk more accurately in HD 
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Figure 4. Univariate correlation of T50Change and absolute T50Change. (A) Overall cumulative incidence functions 
stratified by median T50Change (=−22.7%). (B) Overall cumulative incidence functions stratified by median 
T50Follow up (=192.5 min). Patients at risk and total events per group are reported below the graphs. (C) Predicted 
cardiovascular death incidence functions stratified by median T50Change. (D) Predicted cardiovascular death 
incidence functions stratified by median T50Follow up. Number of lethal cardiovascular events are reported below 
the graphs. Log-rank statistics was used for comparison of incidence functions. p-values are reported in the 
upper right corner of each graph.
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patient, which face longitudinal weakening of their “natural“ calcification resistance. By analogy, prognosis of 
e.g. calcific aortic stenosis is not only determined by the absolute reduction of valve area but also the rapidity 
of stenosis progression which is especially high in HD patients29,30. Based on this reasoning, it is tempting to 
speculate that preventing a decline of T50 in HD patients or restoring T50 in those who present with declining T50 
might favourably affect the future clinical course. Importantly, T50 represented the only modifiable risk factor in 
our adjusted Cox model for mortality. In fact, first interventional pilot studies suggest that increasing dialysate 
magnesium and bicarbonate act concordantly to prolong T50 time in HD patients31. Similarly, phosphate binder 
therapy has the potential to elevate T5032.
Our study has several limitations. Although this is the first study to assess individual dynamics of serum cal-
cification propensity in HD patients it doesn’t fulfil all criteria for studying change, since T50 was only assessed 
from sera collected at two not three different time points. In addition, the study design required exclusion of 
patients who did not survive the first 24 months FU period or who missed timely FU. Therefore, the study pop-
ulation was significantly enriched for survivors, which limits the generalizability of our results and explains the 
lack of predictive potential of T50Baseline. Due to the relatively low number of cardiovascular deaths we were unable 
to fully adjust the Cox model for cardiovascular mortality. The study design and post hoc character of the study 
preclude conclusions regarding causality and therefore, the pathophysiologic mechanism linking declining T50 
to excess mortality remains elusive. We could not consider dietary calcium or phosphorus intake since these 
parameters were not available in the dataset. Lastly, although these data provide a fascinating new perspective 
on intra-individual serum calcification resistance and the interpretation of the T50 test, larger scaled studies are 
needed to replicate and develop these results.
In conclusion, longitudinally monitoring changes in T50-time in HD patients might offer a suitable tool to 
identify patients at risk for adverse outcome and open the conceptual possibility of basing multimodal and per-
sonalized therapeutic interventions on longitudinal changes of T505. Larger scaled prospective interventional 
studies are needed to put this concept to a test.
Methods
Subjects/Study population. This study was undertaken in a subset of patients of the original “rISk strAt-
ification in end stage Renal disease” - (ISAR)-cohort, a multicentre, prospective longitudinal observatory cohort 
study33. Between 2010 and 2013, 519 stable HD patients from 17 dialysis centres in Munich, Germany and the 
surrounding area were included. Out of these patients the present study included 188 patients, which were still 
alive and active in the study after the first FU period of 24 months with a maximum spread of ±3.2 months and 
for whom sera were available at both baseline and follow-up. Patients for whom timely 24 [23–25] months FU had 
been missed were excluded a priori (Fig. 1). Patients were ≥18 years of age, had an HD vintage of least 90 days 
and gave written and informed consent. The ISAR study was approved by the ethics committees of the Klinikum 
rechts der Isar, Technical University Munich and of the Bavarian State Board of Physicians33. It was carried out in 
accordance with the declaration of Helsinki. Written informed consent was obtained from all participants. The 
study was registered under ClinicalTrials.gov identifier: NCT01152892 prior to its start. For the derived study, no 
additional ethics committee approval was sought. For more details, we refer to the study protocol33.
Clinical data assessment. Patients’ age, comorbidities and medication at FU were assessed using medical 
records from the contributing dialysis centres. Comorbidities were recorded following an adapted version of the 
Charlson Comorbidity Index (CCI) for ESRD as introduced by Liu et al.34. BMI at FU was calculated as body 
weight/height2 [kg/m2]. Access type (fistula or permanent catheter) was determined at time of FU and considered 
constant for the consecutive observation period. Information on dialysis prescription (Ultrafiltration, session 
duration, Kt/V as a measure of dialysis efficiency, HD/HDF, anticoagulation) was provided by the contributing 
centres. All patients underwent regular bicarbonate dialysis with synthetic membranes. For details, we refer to 
the study protocol33.
Model
all-cause mortality
p - value
CV mortality
p - valueHR per 1 SD decline 95 % CI HR per 1 SD decline 95 % CI
Crude T50Change 1.74
1.2 to 
2.51 0.003 2.050 1.12 to 3.75 0.02
Model 1 1.71 1.17 to 2.51 0.006 2.140 1.15 to 3.97 0.02
Model 2 1.71 1.16 to 2.51 0.007 — — —
Model 3 1.61 1.09 to 2.36 0.02 — — —
Model 4* 1.51 1.04 to 2.2 0.03 — — —
Table 3. All-cause mortality: Crude and adjusted hazard ratios of T50Change per SD decline (=30.5%). Crude 
and adjusted hazard ratios (HR) are presented per 1SD decrease (=30.5%) of T50 during the 24 months follow 
up. All-cause mortality was the dependent variable. Model 1 includes age, sex, body mass index; Model 2 
additionally includes the adapted Charlson Comorbidity Index; Model 3 additionally includes albumin; Model 
4 additionally includes log transformed Interleukin-6; *addition of phosphate did not significantly improve the 
model.
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Endpoints. The primary outcome parameters for the ISAR-trial and this project were all-cause and CV mor-
tality. Observation for all-cause and cause-specific mortality started the day after the 24 month FU visit. In the 
absence of a final medical report stating the cause of death, attending physicians and relatives were contacted to 
confirm death and gather available information, based on which the ISAR-study physician board assigned each 
case an underlying cause of death. CV mortality (n = 17) was due to sudden cardiac death (n = 6), myocardial 
infarction (n = 4), heart failure (n = 1), cardiac surgical procedure (n = 2), pulmonary embolism (n = 1), major 
stroke (n = 2) and rupture of aortic aneurysm (n = 1). Non-CV lethal events (n = 26) comprised infectious events, 
gastrointestinal bleeding, non-CV related surgery, withdrawal from treatment, chronic pulmonary disease, malig-
nant diseases and unknown causes of death.
Blood specimen collection and Laboratory methods. Serum was collected prior to a midweek dial-
ysis session at time of inclusion and at FU. Serum was centrifuged after 30 min of resting at room temperature, 
aliquoted and frozen at −20 °C, transferred to our laboratory on dry ice and stored at −80 °C for later analysis. 
Routine laboratory analysis was performed by ISO certified laboratories. IL-6 was determined using BD Flex-sets 
on a FACS Canto II and BD Diva software following the manufacturer’s instructions. BD FCAP Array software 
3.0 was used for analysis. Ionized magnesium levels were determined from frozen sera using the Nova 8 Analyzer 
(Nova Biomedical, Waltham, MA, US). T50 was determined at previously described by Pasch et al.6,10. Sera had 
never been thawed prior to analysis and were sent to Bern on dry ice and analyzed in a blinded manner. Median 
storage duration was 48 [42–70] or 24 [18–47] months for samples collected at baseline or 24 months follow, 
respectively.
Statistical Analysis. Statistical analysis was performed using IBM SPSS Statistics 23 and R version 3.3.2 
software. We present mean ± standard deviation (SD), median and [interquartile-range] or counts and (% of 
superset) for normally distributed data, non-normally distributed metric and ordinal variables or nominal data, 
respectively. IL-6 levels were natural logarithm-(ln)-transformed to adjust for skewness of distribution.
Paired t-test was used to compare differences between absolute T50-values at baseline and 24 months FU. Change 
in T50 (T50Change) was calculated as (T50Follow up−T50Baseline)/T50Baseline and expressed in percent. Subjects were stratified 
above and below the median of T50Change and T50Follow up, respectively for description of baseline characteristics at 
time of 24 months FU. Group differences were tested using unpaired t-test, Mann-Whitney-U, χ²-test and paired 
t-test as appropriate. Additionally, we assessed associations of continuous variables with T50Change and T50Follow up 
using Pearson correlation. Median T50Follow up and median T50Change were also used to stratify patients for univariate 
Kaplan-Meier survival analysis of all-cause and CV mortality. Cumulative incidence functions were estimated for 
CV and non-CV deaths to account for competing risks. Log-rank tests were performed to compare (cause specific) 
hazard rates between relevant groups. Patients were censored at time of transplantation or at time of loss to FU.
A multivariable linear regression model was built including age, sex, BMI, coronary heart disease (CHD), 
peripheral arterial occlusive disease (PAOD), diabetes, hypertension, intake of calcium containing phosphate 
binders, Vitamin D3 supplementation and laboratory parameter (calcium, magnesium, albumin, phosphate, 
intra-individual Δ-phosphate (=phosphateFollow up−phosphateBaseline [mmol/l]) and Δ-calcium, Δ-albumin to 
identify factors that were associated with T50Change. Coefficients of regression are reported per 1 SD increase of 
the regressor. Variance of inflation factors were below 2 for all entered variables. Cox proportional hazard models 
were fit to the data to characterize the association of T50Change with all-cause mortality. Proportionality of hazard 
rates was investigated by the use of Schoenfeld residuals and a statistical test for proportional hazard proposed by 
Grambsch and Therneau35.
The models were adjusted for demographic factors (age, gender, BMI), comorbidities (following the adapted 
CCI as proposed by Liu et al.34), albumin and ln-transformed IL-6. Hazard ratios (HR) and 95 % confidence inter-
val (95% CI) are reported per 1SD of T50Change (≈30.5 % change in T50) during the 24 months FU, 2 of 188 cases 
were censored before the earliest event had occurred. The datasets generated during and/or analysed during the 
current study are available from the corresponding author on reasonable request.
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